Rory S. Bennett

Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Ten-day venetoclax plus fluconazole with azacitidine or low-dose cytarabine for elderly/unfit AML patients in resource-limited settings.

Ten-day venetoclax plus fluconazole with azacitidine or low-dose cytarabine for elderly/unfit AML patients in resource-limited settings.

Journal: Leukemia & lymphoma
Published: May 04, 2026

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Journal: Internal medicine journal
Published: January 06, 2026

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study.

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study.

Journal: HemaSphere
Published: December 17, 2025

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 18, 2025

Routine magnetic resonance central nervous system imaging may be avoided in high-risk systemic diffuse large B-cell lymphoma with negative cerebrospinal fluid analyses.

Routine magnetic resonance central nervous system imaging may be avoided in high-risk systemic diffuse large B-cell lymphoma with negative cerebrospinal fluid analyses.

Journal: Leukemia & lymphoma
Published: January 15, 2025

A single-institution study of allograft outcomes for chronic lymphocytic leukaemia over 20 years.

A single-institution study of allograft outcomes for chronic lymphocytic leukaemia over 20 years.

Journal: Internal medicine journal
Published: November 26, 2024

SOHO State of the Art Updates and Next Questions | Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma.

SOHO State of the Art Updates and Next Questions | Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia
Published: February 20, 2024

Update on the management of relapsed/refractory chronic lymphocytic leukemia.

Update on the management of relapsed/refractory chronic lymphocytic leukemia.

Journal: Blood cancer journal
Published: December 19, 2023

Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.

Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.

Journal: EJHaem
Published: November 28, 2023

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.

Journal: Blood advances
Published: July 28, 2023

Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.

Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.

Journal: Journal of hematology & oncology
Published: May 09, 2023

Ocular toxoplasmosis during frontline venetoclax therapy for chronic lymphocytic leukaemia - more than meets the eye.

Ocular toxoplasmosis during frontline venetoclax therapy for chronic lymphocytic leukaemia - more than meets the eye.

Journal: EJHaem
Published: February 23, 2023
Showing 1-12 of 23

Last Updated: 09/26/2026